Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib

Blood. 2010 Dec 23;116(26):6144-5; author reply 6145-6. doi: 10.1182/blood-2010-07-296954.

Authors

Wendy Deenik, Bronno van der Holt, Jeroen J W M Janssen, Isabel W T Chu, Peter J M Valk, Gert J Ossenkoppele, Ilse P van der Heiden, Pieter Sonneveld, Ron H N van Schaik, Jan J Cornelissen

PMID: 21183698
DOI: 10.1182/blood-2010-07-296954

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

ATP Binding Cassette Transporter, Subfamily B
ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics*
Antineoplastic Agents / administration & dosage*
Benzamides
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm / genetics*
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
Piperazines / administration & dosage*
Polymorphism, Single Nucleotide / genetics*
Prognosis
Pyrimidines / administration & dosage*

Substances

ABCB1 protein, human
ATP Binding Cassette Transporter, Subfamily B
ATP Binding Cassette Transporter, Subfamily B, Member 1
Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate